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Physicians face a number of challenges when developing 
guidelines, as the context in which we practice medicine 
is ever changing. In this edition of the Korean Journal 
of Internal Medicine, Korean experts in the fields of 
infectious disease, hematology–oncology, laboratory 
medicine, internal medicine, and methodology took 
that challenge. Their task was to develop evidence-
based guidelines for febrile neutropenia [1]. Febrile 
neutropenia is a consequence of collateral damage caused 
by chemotherapy for an underlying hematological disease 
and has a high mortality rate that clinicians must tackle.
These guidelines are very helpful, as they provide 
practical guidance for clinicians that will help young 
physicians as well as more experienced physicians. The 
guidelines consist of text and tables for decision making 
and incorporate dosing recommendations and practical 
figures with algorithms to follow. This is not always seen 
in other guidelines [2]. Both the process of developing 
these Korean guidelines and the means by which the 
results were obtained were made very transparent which 
is not always provided by others. Another positive aspect 
of these guidelines is that the grading system used is 
identical to that used by the Infectious Diseases Society 
of America (ISDA) [2,3]. This allows the foreign reader 
to understand the strength of the recommendations and 
the quality of the evidence. These Korean guidelines will 
be discussed widely in the academic world because they 
provide additional insights into the clinical care of patients 
with febrile neutropenia.
In the development of given guidelines, it is important 
to remember who is addressed. American or European 
guidelines might not adequately represent or even 
address the same issues as those that occur in Korea. 
The epidemiology might differ, and the approval and 
availability of certain drugs has to be considered. This 
cannot be provided by outside guidelines. Regional 
guidelines (e.g., European, Asian-Pacific, or Australian) 
might provide physicians with some insight, but they will 
always need to be adjusted for the respective countries. 
However, I would like to offer one word of caution, which 
is to point out the necessity of ensuring that guidelines are 
updated on a regular basis.
What can I say about the quality of the guidelines? 
Today, certain qualities are required: the scope and 
purpose of the guidelines, followed by stakeholder 
involvement, rigor of development, clarity of presentation, 
applicability, and editorial independence [4]. These 
guidelines have met these criteria. Interestingly, besides 
the authors themselves, advice from other Korean 
experts in this field of expertise was incorporated via a 
questionnaire (full data not presented in the publication 
but available from the corresponding author) [1].
Funding from industry played no role in these guidelines 
and was not involved during their development. This is 
important for guaranteeing independence, which is not 
provided when representatives of companies are present. 
Even their simply sitting in as learning observers is 
considered inappropriate. Obviously, this did not occur 
with these guidelines.
When considering patient care, it is also important to 
understand the limitations that national approval places 
on the use of treatments, such as anti-infective agents. 
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This always needs to be considered in national guidelines. 
During the development of guidelines, it is therefore 
essential to ask three simple questions repeatedly: What 
do clinicians want? Which option is better for patients? 
Is the chosen option truly better? [5] Understandably, 
physicians cannot change national legislation, but 
government officials should consider their input. On 
another note, the potential cost implications of applying 
the recommendations were considered in these guidelines.
It would be inappropriate for me discuss certain 
recommendations that I might or might not agree 
with. Nevertheless, it is pivotal to mention that the 
scientific process involved in the development of these 
guidelines was sound. The authors offer evidence-based 
recommendations by conducting an evaluation of available 
data and reviewed their importance for Korea. This 
evaluation was not influenced by any industry involvement 
and was reviewed by the authors’ peers, who were allowed 
to comment via a questionnaire. This process is fairly 
unique in the world of guidelines, and others should follow 
in the footsteps of these Korean experts.
In summary, I would like to applaud the organizer, 
the National Evidence-based Healthcare Collaborating 
Agency, together with a team of experts from various 
Korean academic societies for completing this endeavor 
in an amazingly short time. These guidelines are very 
clinically orientated and practical, and they will hold 
medical care in this specific field of medicine to a high 
standard. (Korean J Intern Med 2011;26:135-136)
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